-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Anti-infective drugs refer to various drugs used to treat infections caused by pathogens (viruses, chlamydia, mycoplasma, rickettsia, bacteria, spirochetes, fungi, worms, etc.
)
.
It is reported that the listed companies in the domestic anti-infective drug industry include Puluo Pharmaceutical, Zhejiang Pharmaceutical, North China Pharmaceutical, and Jingxin Pharmaceutical
.
For example, Zhejiang Medicine stated that the main research and development directions in the future mainly include anti-infective drugs, vitamin drugs, diabetes drugs, and anti-tumor drugs
.
As of the end of 2021, the company has a total of 42 new drug and new product projects under development, 11 of which have been declared for production, and 17 of which have been declared for quality and efficacy consistency evaluation of generic drugs and are under development
.
Recently, Zhejiang Medicine issued an announcement that the anti-infective drug Linezolid Glucose Injection passed the consistency evaluation of generic drugs
.
Data show that linezolid is an inhibitor of bacterial protein synthesis and is suitable for the following infections in adults and children caused by susceptible Gram-positive bacteria: nosocomial pneumonia, community-acquired pneumonia, complex skin or skin and soft tissue infections, These include diabetic foot infections without osteomyelitis, uncomplicated skin or skin and soft tissue infections, and vancomycin-resistant enterococci
.
Puluo Pharmaceutical also recently issued an announcement on anti-infective drugs.
Its subsidiary Zhejiang Puluo Kangyu Pharmaceutical Co.
, Ltd.
received the PQ (pre-qualification) confirmation letter issued by the World Health Organization (WHO), and the company's levofloxacin tablets passed the WHO's PQ audit
.
The data show that levofloxacin has strong antibacterial effect and broad antibacterial spectrum, and is the first-line drug for clinical anti-infection
.
It can be used to treat infections caused by sensitive bacteria in adults (≥18 years)
.
The anti-infective drug "Cefoxitin Sodium for Injection (1.
0g/2.
0g)" of North China Pharmaceutical Hebei Huamin Pharmaceutical Co.
, Ltd.
was also recently approved by the Drug Evaluation Center of the State Drug Administration, and the quality and efficacy of generic drugs are consistent.
sexual evaluation
.
Data show that cefoxitin sodium for injection is an anti-infective drug
.
It is suitable for upper and lower respiratory tract infections, bone and joint soft tissue infections, endocarditis infections and other infections caused by pathogenic bacteria that are sensitive to this product, especially for aerobic and anaerobic mixed infections, as well as for those caused by β-lactamase production Infections caused by bacteria sensitive to this product
.
In the field of anti-infective drugs, many companies are actively deploying
.
In addition to the above companies, Jingxin Pharmaceutical stated that the company's existing drugs are mainly anti-infective drugs such as levofloxacin tablets, ciprofloxacin tablets, clarithromycin tablets, etc.
Since its establishment to the beginning of its listing, Jingxin Pharmaceutical has been operating quinolones Anti-infective drug API is the main business
.
Sunflower said that the company's leading products cover anti-infective drugs, cardiovascular drugs, digestive system drugs and other fields
.
Zhejiang Huahai Pharmaceutical also stated that in terms of preparations, the company's products cover cardiovascular, mental disorders, nervous system, anti-infective and other therapeutic fields, mainly including valsartan tablets, losartan potassium tablets, irbesar Tan Hydrochlorothiazide Tablets, Paroxetine Hydrochloride Tablets, Donepezil Hydrochloride Tablets, Levetiracetam Tablets, Lamotrigine Controlled Release Tablets, Ambrisentan Tablets,
etc.
It is understood that infectious diseases refer to when pathogenic microorganisms or opportunistic pathogenic microorganisms invade the host, grow, reproduce and release toxins, resulting in the imbalance of the microecological balance in the body and becoming a pathophysiological disease.
Since the beginning of the 21st century, life sciences Biotechnology and information technology have developed in parallel to become the underlying common technologies that support economic and social development, and achievements in biotechnology innovation, biomedical development and application are becoming more and more apparent.
The development of anti-infective drugs has also made progress amid challenges.
Global pharmaceutical market It can be divided into chemical drug market and biological drug market
.
In terms of therapeutic areas, in 2020, the top market segments of the global pharmaceutical market are gastrointestinal and metabolic drugs, systemic anti-infective drugs and anti-tumor drugs, accounting for 14.
5% of the global pharmaceutical market size, respectively.
12.
4% and 11.
6%
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
)
.
It is reported that the listed companies in the domestic anti-infective drug industry include Puluo Pharmaceutical, Zhejiang Pharmaceutical, North China Pharmaceutical, and Jingxin Pharmaceutical
.
For example, Zhejiang Medicine stated that the main research and development directions in the future mainly include anti-infective drugs, vitamin drugs, diabetes drugs, and anti-tumor drugs
.
As of the end of 2021, the company has a total of 42 new drug and new product projects under development, 11 of which have been declared for production, and 17 of which have been declared for quality and efficacy consistency evaluation of generic drugs and are under development
.
Recently, Zhejiang Medicine issued an announcement that the anti-infective drug Linezolid Glucose Injection passed the consistency evaluation of generic drugs
.
Data show that linezolid is an inhibitor of bacterial protein synthesis and is suitable for the following infections in adults and children caused by susceptible Gram-positive bacteria: nosocomial pneumonia, community-acquired pneumonia, complex skin or skin and soft tissue infections, These include diabetic foot infections without osteomyelitis, uncomplicated skin or skin and soft tissue infections, and vancomycin-resistant enterococci
.
Puluo Pharmaceutical also recently issued an announcement on anti-infective drugs.
Its subsidiary Zhejiang Puluo Kangyu Pharmaceutical Co.
, Ltd.
received the PQ (pre-qualification) confirmation letter issued by the World Health Organization (WHO), and the company's levofloxacin tablets passed the WHO's PQ audit
.
The data show that levofloxacin has strong antibacterial effect and broad antibacterial spectrum, and is the first-line drug for clinical anti-infection
.
It can be used to treat infections caused by sensitive bacteria in adults (≥18 years)
.
The anti-infective drug "Cefoxitin Sodium for Injection (1.
0g/2.
0g)" of North China Pharmaceutical Hebei Huamin Pharmaceutical Co.
, Ltd.
was also recently approved by the Drug Evaluation Center of the State Drug Administration, and the quality and efficacy of generic drugs are consistent.
sexual evaluation
.
Data show that cefoxitin sodium for injection is an anti-infective drug
.
It is suitable for upper and lower respiratory tract infections, bone and joint soft tissue infections, endocarditis infections and other infections caused by pathogenic bacteria that are sensitive to this product, especially for aerobic and anaerobic mixed infections, as well as for those caused by β-lactamase production Infections caused by bacteria sensitive to this product
.
In the field of anti-infective drugs, many companies are actively deploying
.
In addition to the above companies, Jingxin Pharmaceutical stated that the company's existing drugs are mainly anti-infective drugs such as levofloxacin tablets, ciprofloxacin tablets, clarithromycin tablets, etc.
Since its establishment to the beginning of its listing, Jingxin Pharmaceutical has been operating quinolones Anti-infective drug API is the main business
.
Sunflower said that the company's leading products cover anti-infective drugs, cardiovascular drugs, digestive system drugs and other fields
.
Zhejiang Huahai Pharmaceutical also stated that in terms of preparations, the company's products cover cardiovascular, mental disorders, nervous system, anti-infective and other therapeutic fields, mainly including valsartan tablets, losartan potassium tablets, irbesar Tan Hydrochlorothiazide Tablets, Paroxetine Hydrochloride Tablets, Donepezil Hydrochloride Tablets, Levetiracetam Tablets, Lamotrigine Controlled Release Tablets, Ambrisentan Tablets,
etc.
It is understood that infectious diseases refer to when pathogenic microorganisms or opportunistic pathogenic microorganisms invade the host, grow, reproduce and release toxins, resulting in the imbalance of the microecological balance in the body and becoming a pathophysiological disease.
Since the beginning of the 21st century, life sciences Biotechnology and information technology have developed in parallel to become the underlying common technologies that support economic and social development, and achievements in biotechnology innovation, biomedical development and application are becoming more and more apparent.
The development of anti-infective drugs has also made progress amid challenges.
Global pharmaceutical market It can be divided into chemical drug market and biological drug market
.
In terms of therapeutic areas, in 2020, the top market segments of the global pharmaceutical market are gastrointestinal and metabolic drugs, systemic anti-infective drugs and anti-tumor drugs, accounting for 14.
5% of the global pharmaceutical market size, respectively.
12.
4% and 11.
6%
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
